Vera Therapeutics, Inc. (VERA)
Nasdaq: VERA · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Feb 26, 2026 | Feb 28, 2025 | Mar 27, 2024 | Mar 28, 2023 | Mar 28, 2022 | · |
| Research and development | 215,256 | 126,172 | 78,225 | 68,993 | 22,484 | 45,206 |
| General and administrative | 100,217 | 40,998 | 23,787 | 21,910 | 11,918 | 4,039 |
| Total operating expenses | 315,473 | 167,170 | 102,012 | 90,903 | 34,402 | 52,241 |
| Operating income | -315,473 | -167,170 | -102,012 | -90,903 | -34,402 | -52,241 |
| Interest expense | 7,531 | 7,626 | 3,786 | 992 | 20 | 166 |
| Interest and investment income | 24,479 | 20,714 | 7,979 | 1,750 | 15 | 8 |
| Total non-operating income (expense) | 15,859 | 15,023 | 6,023 | 1,848 | 1,794 | -1,171 |
| Income before income taxes | -299,614 | -152,147 | -95,989 | -89,055 | -32,608 | -53,412 |
| Income tax expense | 1 | 1 | 1 | 1 | 1r | -1 |
| Net income | -299,615 | -152,148 | -95,990 | -89,056 | -32,609 | -53,413 |
| Earnings per share, basic | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | · |
| Earnings per share, diluted | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.43 | -166.93 |
| Weighted average shares, basic | 64,233,814 | 55,326,680 | 42,707,072 | 26,570,676 | 13,435,706 | · |
| Weighted average shares, diluted | 64,233,814 | 55,326,680 | 42,707,072 | 26,570,676 | 13,435,706 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 13,435,706 | 319,963 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted